Patient-Reported Satisfaction with Palbociclib Combination Therapies for Advanced or Metastatic Breast Cancer

Share on: 

Patient Reported Treatment Satisfaction with Palbociclib Combination Therapies for HR+/HER2– Advanced or Metastatic Breast Cancer in Multiple Countries
Mitra D, Darden C, McSorley D, Davis K, Band J, Iyer S

Return to RTI-HS ISPOR Baltimore webpage to see what else we presented

Christina Darden, BS
Director, Surveys and Observational Studies
RTI Health Solutions

Patient experiences with breast cancer treatments have been studied and reported, but there is limited information about patient satisfaction with newer targeted treatments post approval in real-world settings. 

We conducted a web-based survey of patients with advanced or metastatic breast cancer who were receiving palbociclib plus an aromatase inhibitor or palbociclib plus fulvestrant in the US, Canada, and Germany. 

The survey included the Cancer Therapy Satisfaction Questionnaire which has three domains:  expectations of therapy, feelings about side effects, and satisfaction with therapy. 

The results highlighted that patients had high expectations of and satisfaction with their combination therapy, and that the majority felt the side effects were as or better than expected. Most patients reported that the benefits of their therapy met or exceeded their expectations and if given the choice, they would take the combination therapy again.
Results were consistent across countries, and overall, patients were satisfied with their treatment.

Related Services:
Staff Members: